| Literature DB >> 36248406 |
Yu-Qian Shi1, Yi Wang1, Xi-Ting Zhu1, Rui-Yang Yin1, Yi-Fu Ma1, Han Han2, Yan-Hua Han3, Yue-Hui Zhang3.
Abstract
Polycystic ovary syndrome (PCOS) is a lifelong reproductive endocrine disease, which is the most common cause of anovular infertility. Modern medicine mainly treats infertile patients with PCOS by improving living habits, ovulation induction therapy, and assisted reproductive technology (ART), but the effect is not satisfied. Complementary alternative medicine (CAM) has conspicuous advantages in the treatment of PCOS infertility due to its good clinical efficacy, wide mechanism of action, and no obvious adverse reactions, but its safety and effectiveness in the treatment of PCOS infertility have not been proved. Based on the existing clinical and experimental studies, this paper looks for the therapeutic effect and the mechanism behind it, and explores the safety and effectiveness of its treatment in PCOS infertility, in order to provide reference for future clinical treatment and experimental research.Entities:
Year: 2022 PMID: 36248406 PMCID: PMC9568292 DOI: 10.1155/2022/5076306
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
List of reference numbers corresponding to traditional Chinese medicine, acupuncture and other therapies.
| CAM treatment modalities | Mechanism of action | Reference range |
|---|---|---|
| CHM (monomers, compound, compound enema) | Monomers (BBR, CRY, QUE), compound (BSD, GFP, STP, and ZYP) in the treatment of patients with PCOS infertility is to improve IR and glucose and lipid metabolism disorder, improve sex hormone levels, and promote follicular development | [ |
| Acupuncture (general acupuncture, EA, moxibustion and warm acupuncture, other treatment modalities related to acupuncture) | Lose weight, improves depression, regulates the HPOA, promotes ovulation, and improves ER. | [ |
| Other therapies (vitamin and trace element supplementation and other nutrients, weight loss, exercise, and other healthy lifestyles) | Nutrient supplementation improves FSH levels and chronic low-intensity inflammatory response, and micronutrient supplementation promotes paired follicle development in PCOS infertility patients. Weight loss can improve insulin sensitivity, HA, and follicular development in PCOS infertility patients. Exercise modulates the HPOA to improve sex hormone disorders and increase ovulation and pregnancy rates in patients with PCOS infertility. | [ |
RCT and results of monomers of CHM.
| ID | Design | Test subjects | Sample size | Grouping situation | Outcomes | Ethical clearance number |
|---|---|---|---|---|---|---|
| 24 | RCT | Human | 78 | Control group: Non-PCOS infertility | Observation group B: mTOR mRNA ↓ ( | [2017] No. 158 |
| Observation group A : PCOS infertility | ||||||
| Observation group B: PCOS infertility + BBR | ||||||
| 27 | RCT | Human | 644 | Berberine group(A): BBR + LET placebo | The live birth rate, PR and OR of B and C were similar and significantly higher than those of berberine group. | ChiCTR-TRC-09000376 |
| LET group(B): LET + BBR placebo | ||||||
| Combination group(C): LET + BBR | ||||||
| 34 | RCT | Human | 84 | Treatment group: QUE | Treatment group: adiponectin ↑ HOMA-IR ↓、 T ↓、 LH ↓、 FBS ↓ All <0.009 | IRCT2013112515536N1 |
| Control group: Placebo | ||||||
| 35 | RCT | Human | 78 | Treatment group: QUE | Resistin concentration: 2.07 ± 0.23 vs. 2.88 ± 0.40 ng/ml mRNA levels: 0.64 ± 0.58 vs. 1 ± 0.56 | IRCT2016082215536N4 |
| Control group: Placebo | T: 0.72 ± 0.15 vs. 0.76 ± 0.12 ng/ml LH: 8.05 ± 2.88 vs. 8.77 ± 1.99 mIU/ml | |||||
| All | ||||||
| 31 | RCT | Rats | 60 | Normal rats: | Observation group B: T↓、E2↓、 LH↓、 LH/FSH ↓ Inhibin B、 lutein mRNA and protein expression ↓ Activin A mRNA and protein expression ↑ | All protocols were conducted in accordance with the guidance suggestions for the care and use of laboratory animals, formulated by the Ministry of Science and Technology of China. |
| PCOS rat A: Normal saline | ||||||
| PCOS rat B: CRY | ||||||
| All | ||||||
| 32 | RCT | Rats | 60 | Blank control group | Weight ↓, ovarian mass ↓, LH ↓, LH/FSH ↓, T ↓, TNF- | No. 20190103 |
| PCOS group | ||||||
| PCOS + HMGB1 group | ||||||
| PCOS + HMGB1 + CRY | ||||||
| 36 | RCT | Rats | 24 | Control group (C): carboxymethyl cellulose aqueous solution | T↓ : | BAS#0256 |
| PCOS group (M): LET | E2↓ : | |||||
| Metformin group ( | P↑ : | |||||
| All |
RCT and results of TCM compound.
| ID | Design | Model | Sample size | Grouping situation | Outcome | Ethical clearance number |
|---|---|---|---|---|---|---|
| 54 | RCT | Human | 80 | Observation group: Daing 35 + CC | PR: 37.50% (15/40) vs. 15% (6/40) Number of follicles ↓、ovarian volume ↓、T ↓、 LH ↓ Endometrial thickness ↓、E2↑ | This trial was approved by the Ethics Committee of Zijin county maternal and Child Health hospital, Guangdong Province, and the ethical approval number is not explicitly mentioned in the text |
| 44 | RCT | Human | 56 | Observation group: metformin + ethinyl estradiol cyproterone tablets + GFP | Total efficiency: 96.4% (27/28) vs. 71.4% (20/28) pregnancy rate: 67.9% (19/28) vs. 35.6% (10/28) | This trial was approved by the ethics committee of Anyang People's hospital in Henan Province; the ethics approval number is not explicitly mentioned in the text |
| 55 | RCT | Human | 100 | Observation group: ethinyl estradiol cyproterone tablets + ZYP | Total efficiency: 100% (50/50) vs. 80% (40/50) | This trial was approved by the Ethics Committee of the Dazhou hospital of integrative medicine, the ethical approval number is not explicitly mentioned in the text |
| 48 | RCT | Human | 64 | Observation group: estradiol valerate tablets + progesterone capsules + ZYP | Pregnancy rate: 40.63% (13/32) vs. 15.63%(5/32) survival rate: 28.13% (9/32) vs. 3.13% (1/32) | This trial was approved by the thics Committee of Nantong Chinese hospital, the ethical approval number is not explicitly mentioned in the text |
| 49 | RCT | Human | 60 | Observation group: Chinese herbal enema ( | Uterine spiral artery RI: 0.63 ± 0.03 vs. 0.66 ± 0.03 | This trial has been approved by the Ethics Committee of Suzhou hospital of traditional Chinese medicine, Jiangsu Province, and the ethics approval number is not explicitly mentioned in the text |
| 39 | RCT | Rats | 50 | Blank control group (K) | In PCOS-IR rats with upregulated ovarian FSHR and Cyp19a1 mRNA levels, LDP (3.6 g-kg-1-d-1) significantly reversed the upregulated phosphorylation of IRS-1 (S307) and the downregulated phosphorylation of PI3Kp85 | This trial has been approved by the ethics committee of the iangsu key laboratory for the evaluation and translation of traditional Chinese medicine, and the ethics approval number is not explicitly mentioned in the text |
| 43 | RCT | Rats | 72 | Blank control group (K) | Experimental group HS-CPR ↓, IL-6 ↓, TNF- | SYXK2018-0126 |
| 42 | RCT | Rats | 84 | Control group | GFP treatment group: atresia follicles ↓, cystic follicles ↓, mature follicles ↑ and corpus luteum ↑ | SYXK2018-0126 |
Blank control group (K), model control group (M), low dose group (D), medium dose group (Z), high dose group (G), positive drug (Y).
RCT and results of acupuncture.
| ID | Design | Sample size | Interventions | Outcomes | Composition | Ethical clearance |
|---|---|---|---|---|---|---|
| 67 | RCT | 86 | Manual acupuncture: CHM + acupuncture sham acupuncture: CHM | PR:46.34% (19/41) vs. 18.42% (7/38) | Acupoints: RN4, EX-CA1, ST29, ST36, SP6 | 2017-569-52–01 |
| 68 | RCT | 86 | Observation group: CC + CHM + acupuncture | PR: 46.5% (20/43) vs. 30.2% (13/43) | Prescription: | This trial was approved by the Ethics Committee of The First People's hospital of Foshan city, Guangdong Province, and the ethical approval number is not explicitly mentioned in the text |
| 69 | RCT | 60 | Observation group: LET + acupuncture | PR: 60.53% (23/38) vs. 27.03% (10/37) | Acupoints: EX-CA1, SP6, RN3 | This trial was approved by the Ethics Committee of Affiliated hospital of Shandong University of traditional Chinese medicine, and the ethical approval number is not explicitly mentioned in the text |
| 72 | RCT | 60 | Observation group: Daying 35 + LET + CHM | Endometrial thickness: 9.58 ± 0.91 mm vs. 6.43 ± 0.87 mm | Prescription: | Trial was approved by Ganzhou traditional Chinese medicine hospital and the ethical approval number is not explicitly mentioned in the text |
| 73 | RCT | 120 | A: Daphne + LET + left right return pill + EA group | Clinical efficacy: 85.0% (43/40) vs. 70.0% (28/40) vs. 60.0% (24/40) | Acupoints: RN4, RN3, RN6, EX-CA1, SP10, ST36, SP6, KI3, KI6 | Trial was approved by Southwest medical university affiliated traditional Chinese medicine hospital and the ethical approval number is not explicitly mentioned in the text |
| 80 | RCT | 103 | Observation group: CC + CHM + moxibustion | Observation group: | Prescription: | Trial was approved by Department of Gynecology, directly under the authority No.2 outpatient department, Henan Province and the ethical approval number is not explicitly mentioned in the text |
| 81 | RCT | 90 | Observation group: Aspirin + CC + CHM + warm acupuncture | Endometrial thickness: 9.85 ± 1.27 mm vs. 7.29 ± 0.931 mm vs. 8.14 ± 1.12 mm | Prescription: | Trial was approved by Tangshan traditional Chinese medicine hospital and the ethical approval number is not explicitly mentioned in the text |
| 82 | RCT | 82 | Observation group: CC + Duoyuan acupuncture | PR: 51.2% (21/41) vs. 26.8% (11/41) | Acupoints: RN12, RN4, RN6, RN3, DU4, DU3, DU2 | Trial was approved by Nanjing University of traditional Chinese medicine and the ethical approval number is not explicitly mentioned in the text |
| 83 | RCT | 60 | Observation group: Acupoint injection of urotropin injection | FSH: 11.36 ± 1.84 IU/L vs. 9.87 ± 1.75 IU/L | Acupoints: EX-CA1, RN3, RN4, SP6 | Trial was approved by Chenghai district People's hospital, Shantou City, Guangdong Province and the ethical approval number is not explicitly mentioned in the text |
| 84 | RCT | 80 | Observation group: CC + Chinese medicine + acupuncture point injection of angelica injection | Total efficiency: 80.0% (32/40) vs. 52.5% (21/40) | Chinese herbs: | Trial was approved by Panyu district central hospital, Guangzhou city, guangdong province and the ethical approval number is not explicitly mentioned in the text |
| 85 | RCT | 125 | Observation group: estradiol valerate tablets + acupuncture + ear acupuncture | Total efficiency: 93.65% (59/63) vs. 80.65% (50/62) | Acupoints: RN6, SP6, RN4, BL20, ST36, LR3, DU4, BL23 | Trial was approved by Sichuan Nanchong traditional Chinese medicine hospital and the ethical approval number is not explicitly mentioned in the text |
| 92 | RCT | 120 | C: Daing 35 + acupuncture | Total efficiency: 95.0% (39/40) vs. 85.0% (34/40) vs. 72.5% (29/40) | Prescription: | Trial was approved by Hubei maternal and child health hospital traditional Chinese medicine and the ethical approval number is not explicitly mentioned in the text |
| 105 | RCT | 60 | Observation group: Daying 35 + acupuncture | OR: 93.3% (28/30) vs. 80.0% (24/30) | Acupoints: RN4, RN6, SP6, ST36, EX-CA1, BL23, BL20, BL21, BL18 | Trial was approved by Lianyungang maternal and child health hospital reproductive medicine center and the ethical approval number is not explicitly mentioned in the text |
| 106 | RCT | 96 | Observation group: acupuncture | Observation group: | Acupoints: RN9, RN7, ST25, ST26, ST24 | Trial was approved by reproductive center of the first affiliated hospital of Tianjin University of traditional Chinese medicine and the ethical approval number is not explicitly mentioned in the text |
| 93 | RCT | 76 | Observation group: EA | Transferable embryo rate: 49.0% (284/580) vs. 41.9% (273/652) | Acupoints: RN12, ST25, SP15, GB26, RN6, RN4, SP10, ST40, ST36, SP9 | SDSZYYSZ20170210 |
| 107. | RCT | 60 | Observation group: dietary control plus exercise + acupuncture | Observation group: | Acupoints: GB26, ST25, SP15, BL23, BL32, ST29, GB41, SJ5 | no.2018019 |
| 76 | RCT | 80 | Observation group: Daying 35 + CHM | Fertility rate: 82.5% (33/40) vs. 60% (24/40) | Prescription: | Trial was approved by Zhaoqing Gaoyao People's hospital and the ethical approval number is not explicitly mentioned in the text |